Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology

An expert discusses the treatment approach for recurrence in Case 1, evaluating the combination of toripalimab + gemcitabine/cisplatin for recurrent disease and considering the potential for re-irradiation, while also reflecting on the treatment strategy in Case 2 and the criteria for determining whether the patient would benefit from additional radiation therapy.

EP: 1.Introduction to Clinical Cases: Toripalimab in Recurrent and Metastatic NPC

EP: 2.Considerations for NPC Therapy: Clinical Perspectives From Radiation Oncology

Now Viewing

EP: 3.Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology

EP: 4.Monitoring Treatment Response in NPC: Looking to EBV Titers and Imaging

EP: 5.Evolving Paradigms: The Role of Systemic Immunotherapy in NPC Treatment

Video content above is prompted by the following:

• Please comment on the treatment approach for recurrence in Case 1.
• What are your thoughts on toripalimab + gemcitabine/cisplatin for recurrent disease?
• Would you consider re-irradiation in this patient?
• What are your thoughts on the treatment approach in Case 2?
• How do you determine whether the patient would benefit from the addition of radiation therapy?

Recent Videos